Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

At present, stroke has become the leading cause of death in China, with hypertension being the primary risk factor and one of the controllable risk factors. Current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. Thus it may exert anti-hypertensive effects through multiple mechanisms. The purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.

Inclusion criteria

• Age≥30 years, ≤ 75 years, regardless of sex;
• Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment.
• Signed and dated informed consent is obtained.

Exclusion criteria

• Blood pressure ≥ 180/110mmHg;
• Planned adjustment of antihypertensive drugs within the next 3 weeks;
• Severe hematologic disorders or significant coagulation abnormalities;
• Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
• Pregnant or lactating women;
• Severe hepatic and renal dysfunction;
• Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
• Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.